Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. 503173-14-6
2. 2,2,2-trifluoro-1-pyridin-2-yl-ethylamine
3. 2,2,2-trifluoro-1-pyridin-2-ylethanamine
4. 2,2,2-trifluoro-1-(pyridin-2-yl)ethan-1-amine
5. Mfcd05864540
6. (s)-2,2,2-trifluoro-1-(pyridin-2-yl)ethan-1-amine
7. Schembl566755
8. Dtxsid00649296
9. Albb-007848
10. Stk500794
11. Akos005171717
12. Ab22803
13. Ab39753
14. Ab39755
15. Sb37375
16. Bs-28515
17. Db-005800
18. Cs-0005384
19. En300-1930762
20. Alpha-(trifluoromethyl)-2-pyridinemethanamine
21. J-506742
22. 2,2,2-trifluoro-1-(2-pyridyl)-1-ethanamine
| Molecular Weight | 176.14 g/mol |
|---|---|
| Molecular Formula | C7H7F3N2 |
| XLogP3 | 0.9 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 5 |
| Rotatable Bond Count | 1 |
| Exact Mass | g/mol |
| Monoisotopic Mass | g/mol |
| Topological Polar Surface Area | 38.9 |
| Heavy Atom Count | 12 |
| Formal Charge | 0 |
| Complexity | 146 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 1 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Drugs in Development
Details:
CT-996 is an investigational, once-daily, oral small molecule GLP-1 receptor agonist being developed for the treatment of both type 2 diabetes and obesity.
Lead Product(s): CT-996
Therapeutic Area: Nutrition and Weight Loss Brand Name: CT-996
Study Phase: Phase IProduct Type: Other Small Molecule
Sponsor: F. Hoffmann-La Roche
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 09, 2024
Lead Product(s) : CT-996
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : F. Hoffmann-La Roche
Deal Size : Inapplicable
Deal Type : Inapplicable
Roche Says Early-Stage Obesity Pill Results Were Based on Just Six Patients
Details : CT-996 is an investigational, once-daily, oral small molecule GLP-1 receptor agonist being developed for the treatment of both type 2 diabetes and obesity.
Product Name : CT-996
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 09, 2024
Details:
CT-996 is an investigational, once-daily, oral small molecule GLP-1 receptor agonist being developed for the treatment of both type 2 diabetes and obesity.
Lead Product(s): CT-996
Therapeutic Area: Nutrition and Weight Loss Brand Name: CT-996
Study Phase: Phase IProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 17, 2024
Lead Product(s) : CT-996
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Genentech Announces Positive Phase I Results of Oral GLP-1 Agonist CT-996 for Obesity
Details : CT-996 is an investigational, once-daily, oral small molecule GLP-1 receptor agonist being developed for the treatment of both type 2 diabetes and obesity.
Product Name : CT-996
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 17, 2024
Details:
CT-996 is a once-daily oral, small molecule GLP-1 receptor agonist being developed for the treatment of obesity and type 2 diabetes (T2D). it was designed to exhibit signaling bias on the GLP-1 receptor, resulting in activation of cAMP.
Lead Product(s): CT-996
Therapeutic Area: Endocrinology Brand Name: CT-996
Study Phase: Phase IProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 10, 2023
Lead Product(s) : CT-996
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : CT-996 is a once-daily oral, small molecule GLP-1 receptor agonist being developed for the treatment of obesity and type 2 diabetes (T2D). it was designed to exhibit signaling bias on the GLP-1 receptor, resulting in activation of cAMP.
Product Name : CT-996
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 10, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ABOUT THIS PAGE
12
PharmaCompass offers a list of CT-996 API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right CT-996 manufacturer or CT-996 supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred CT-996 manufacturer or CT-996 supplier.
PharmaCompass also assists you with knowing the CT-996 API Price utilized in the formulation of products. CT-996 API Price is not always fixed or binding as the CT-996 Price is obtained through a variety of data sources. The CT-996 Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A CT-996 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of CT-996, including repackagers and relabelers. The FDA regulates CT-996 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. CT-996 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A CT-996 supplier is an individual or a company that provides CT-996 active pharmaceutical ingredient (API) or CT-996 finished formulations upon request. The CT-996 suppliers may include CT-996 API manufacturers, exporters, distributors and traders.
CT-996 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of CT-996 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right CT-996 GMP manufacturer or CT-996 GMP API supplier for your needs.
A CT-996 CoA (Certificate of Analysis) is a formal document that attests to CT-996's compliance with CT-996 specifications and serves as a tool for batch-level quality control.
CT-996 CoA mostly includes findings from lab analyses of a specific batch. For each CT-996 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
CT-996 may be tested according to a variety of international standards, such as European Pharmacopoeia (CT-996 EP), CT-996 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (CT-996 USP).
